• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Neurology, Other  • Radiologic Imaging  • Magnetic Resonance Imaging  • Drug Therapy  • Drug Therapy, Other  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

A 3-Year Monthly Imaging Study

Annie W. Chiu, BS; Nancy Richert, MD, PhD; Mary Ehrmantraut, MS; Joan Ohayon, MSN; Shiva Gupta, MD; Giuseppe Bomboi, MD; Deeya Gaindh, AB; Fredric K. Cantor, MD; Joseph A. Frank, MS, MD; Henry F. McFarland, MD; Francesca Bagnato, MD, PhD

Arch Neurol. 2009;66(1):39-43. Published online November 10, 2008 (doi:10.1001/archneur.66.1.noc80047).

Objectives  To investigate the heterogeneity in magnetic resonance image (MRI) patterns of response to interferon beta across patients with multiple sclerosis or within an individual patient over time.

Design, Setting, and Patients  Fifteen patients with relapsing-remitting multiple sclerosis underwent monthly MRIs and clinical examinations (6-month pretherapy phase and 36-month therapy phase) and bimonthly neutralizing antibody tests. On each MRI, the total number of contrast-enhancing lesions was noted. Therapy MRI responders were defined as those with a reduction of 60% or more in the total number of contrast-enhancing lesions during each semester of therapy.

Intervention  Subcutaneous administration of interferon beta-1b, 250 µg, every other day for 3 years.

Main Outcome Measure  Reduction in the number of contrast-enhancing lesions.

Results  Eight patients (53.3%) were MRI responders and 7 (46.7%) were nonresponders. Of those 7, 3 (20.0%) had only an initial optimal reduction of the total number of contrast-enhancing lesions, 2 (13.3%) never reached an optimal response, and 2 (13.3%) had a delayed optimal response. No clear association between neutralizing antibody profile and MRI response was evident.

Conclusions  Multiple MRI evaluations disclose that approximately only half of the patients treated with interferon beta achieve and maintain a full response to the drug over time, although an additional small number of individuals may still restore an optimal response to the drug after an initial failure.

Author Affiliations: Neuroimmunology Branch (Mss Chiu, Ehrmantraut, Ohayon, and Gaindh and Drs Richert, Gupta, Bomboi, Cantor, McFarland, and Bagnato) and Laboratory of Diagnostic Radiology and Research (Dr Frank), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

This Month in Archives of Neurology
Arch Neurol. 2009;66(1):17-18.
FULL TEXT  

Defining Multiple Sclerosis Treatment Response With Magnetic Resonance Imaging: How Much Activity Is Too Much?
Paul S. Giacomini, Douglas L. Arnold, Amit Bar-Or, and Jack P. Antel
Arch Neurol. 2009;66(1):19-20.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Follow-up
Tur et al.
Arch Neurol 2011;68:1421-1427.
ABSTRACT | FULL TEXT  

Defining Multiple Sclerosis Treatment Response With Magnetic Resonance Imaging: How Much Activity Is Too Much?
Giacomini et al.
Arch Neurol 2009;66:19-20.
FULL TEXT